A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma

Trial Profile

A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2013

At a glance

  • Drugs ACT-GRO-777 (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Antisoma Research
  • Most Recent Events

    • 16 Nov 2013 Status changed from active, no longer recruiting to completed according to results published in the Investigational New Drugs.
    • 19 Mar 2010 Preliminary results indicate that AS 1411 has anti-cancer activity and is exceptionally well tolerated compared to most current antineoplastics. Trial data will be submitted to a forthcoming scientific meeting, according to an Antisoma media release.
    • 13 Oct 2009 Initial results from this trial are expected before the end of 2009, according to an Antisoma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top